Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vor Biopharma Inc (VOR)

Vor Biopharma Inc (VOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 111,606
  • Shares Outstanding, K 10,411
  • Annual Sales, $ 0 K
  • Annual Income, $ -116,914 K
  • EBIT $ 0 M
  • EBITDA $ 0 M
  • 60-Month Beta 2.08
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings $-3.33 on 11/13/25
  • Next Earnings Date 03/19/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING:

    Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 0.00% (unch)
  • Historical Volatility 220.11%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,327.40% on 04/09/25
  • IV Low 0.00% on 12/10/25
  • Expected Move (DTE 37) 4.29 (51.65%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 643
  • Put/Call OI Ratio 0.50
  • Today's Open Interest 90,707
  • Open Int (30-Day) 91,435
  • Expected Range 4.02 to 12.60

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -2.35
  • Number of Estimates 3
  • High Estimate -1.11
  • Low Estimate -4.37
  • Prior Year -8.80
  • Growth Rate Est. (year over year) +73.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.50 +58.92%
on 11/20/25
12.82 -19.42%
on 12/09/25
-8.47 (-45.05%)
since 11/10/25
3-Month
6.50 +58.92%
on 11/20/25
49.95 -79.32%
on 09/30/25
-25.67 (-71.31%)
since 09/10/25
52-Week
2.62 +293.97%
on 05/09/25
65.80 -84.30%
on 07/08/25
-9.87 (-48.86%)
since 12/10/24

Most Recent Stories

More News
Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Multiple Late-Stage Data Readouts Reinforce Telitacicept’s Broad Potential Across Autoimmune Diseases Expansion of Executive Leadership and Board Strengthens Global Development Capabilities Expected...

VOR : 10.33 (-3.64%)
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock

BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the...

VOR : 10.33 (-3.64%)
Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock

BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR) (Vor Bio), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced...

VOR : 10.33 (-3.64%)
Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction in proteinuria, with a favorable safety profile Telitacicept demonstrated...

VOR : 10.33 (-3.64%)
Vor Bio to Participate in Upcoming Investor Conferences

BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in...

VOR : 10.33 (-3.64%)
Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Jeremy Sokolove,...

VOR : 10.33 (-3.64%)
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on October 15, 2025, the...

VOR : 10.33 (-3.64%)
Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data

Telitacicept delivered consistent quality-of-life improvement across both treatment and placebo crossover arms 100% of patients on telitacicept for 48 weeks achieved ≥2-point Myasthenia Gravis Activities...

VOR : 10.33 (-3.64%)
Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease

CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host...

VOR : 10.33 (-3.64%)
Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025

CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data...

VOR : 10.33 (-3.64%)

Business Summary

Vor Biopharma Inc. is a cell therapy company pioneering engineered hematopoietic stem cell therapies combined with targeted therapies for the treatment of cancer. Vor Biopharma Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 11.41
2nd Resistance Point 11.00
1st Resistance Point 10.66
Last Price 10.33
1st Support Level 9.91
2nd Support Level 9.50
3rd Support Level 9.16

See More

52-Week High 65.80
Fibonacci 61.8% 41.67
Fibonacci 50% 34.21
Fibonacci 38.2% 26.76
Last Price 10.33
52-Week Low 2.62

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar